3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
86
Kidney Neoplasms
25
Neoplasms
24
Breast Neoplasms
18
Gastrointestinal Stromal Tumors
17
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
15
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
7
Brain Neoplasms
7
Pancreatic Neoplasms
6
Lung Neoplasms
6
Colorectal Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Solid Tumors
5
Small Cell Lung Carcinoma
5
Ovarian Neoplasms
5
Neuroendocrine Tumors
5
Melanoma
5
Glioblastoma
5
Carcinoma
5
Sarcoma
4
Liver Neoplasms
4
Esophageal Neoplasms
4
Clear-cell metastatic renal cell carcinoma
4
Carcinoma, Hepatocellular
4
Astrocytoma
4
Adenoma, Islet Cell
4
Thyroid Cancer, Papillary
3
Interventions
avelumab
2
Sunitinib
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
etelcalcetide hydrochloride
1
enzalutamide
1
bicalutamide
1
aldesleukin
1
Stents
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Leuprolide
1
Kidney Transplantation
1
Interleukin-2
1
Goserelin
1
Flutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Kidney Diseases
×
Sunitinib
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA
NCT00460798
2010-11-16
SUNIKA
Pfizer
Completed
356 enrolled
8 charts